Travere Therapeutics, Inc.
NASDAQ:TVTX · NASDAQ Global Market
+$0.65 today
Vol 6.59M · Avg 2.31M
Income Statement
Follow revenue through to earnings
Review sales, margins, expenses, and profit trends to see what is actually driving reported earnings over time.
Stock Ticker Earnings Waterfall
NASDAQ:TVTX · Revenue to Net Income
Key Ratios
Analysis
$536.2M of revenue converted into -$21.4M of net income for the selected period. Gross margin is 93.7% and net margin is -5.7%, showing how much revenue survives after costs and taxes. EPS is $-0.53, tying the income statement back to per-share earnings.
Income Statement
Annual data · 5 periods
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $490.7M +110.5% | $233.2M +60.5% | $145.2M +32.7% | $109.5M -17.0% | $131.8M | $809.6M | $921.6M | $731.2M |
| Cost of Revenue | $10.3M +33.5% | $7.7M -32.4% | $11.4M +159.0% | $4.4M +15.8% | $3.8M | $725.6M | $804.0M | $882.4M |
| Gross Profit | $480.4M +113.1% | $225.4M +68.5% | $133.8M +27.4% | $105.0M -17.9% | $128.0M | $8.9B | $7.6B | $6.2B |
| Gross Margin | 97.9% +1.2pp | 96.7% +4.6pp | 92.1% -3.8pp | 96.0% -1.1pp | 97.1% | 9.8% | 28.9% | 38.3% |
| Research & Development | $206.0M -27.1% | $282.7M +15.4% | $245.0M +7.8% | $227.3M +13.0% | $201.2M | $983.2M | $1.3B | $490.4M |
| Selling, General & Admin | $337.2M +27.7% | $264.1M -0.5% | $265.5M +34.4% | $197.5M +56.4% | $126.3M | $620.6M | $923.0M | -$1.5B |
| Operating Expenses | $543.2M -1.1% | $549.3M +5.2% | $521.9M +22.8% | $424.9M +29.7% | $327.4M | $5.3B | $7.0B | $8.7B |
| Depreciation & Amortization | $60.7M +39.5% | $43.6M +13.0% | $38.5M +86.0% | $20.7M +62.6% | $12.7M | $374.2M | $1.2B | $631.8M |
| EBITDA | $22.2M +108.4% | -$265.8M +18.5% | -$326.2M -9.0% | -$299.4M -62.3% | -$184.5M | -$15.2B | $6.8B | $9.3B |
| EBITDA Margin | 4.5% +118.5pp | -114.0% +110.6pp | -224.6% +48.9pp | -273.5% -133.6pp | -139.9% | 5.6% | 46.3% | 42.0% |
| Operating Income | -$62.8M +80.6% | -$323.8M +16.6% | -$388.1M -21.4% | -$319.8M -60.4% | -$199.4M | $12.3B | $14.0B | -$15.7B |
| Operating Margin | -12.8% +126.1pp | -138.9% +128.4pp | -267.2% +24.9pp | -292.2% -140.9pp | -151.3% | 16.6% | 24.1% | 22.0% |
| Interest Income | $12.7M -28.6% | $17.8M -18.2% | $21.8M +246.8% | $6.3M +214.9% | $2.0M | -$1.5B | -$1.6B | $405.0M |
| Interest Expense | $10.7M -3.9% | $11.2M -1.3% | $11.3M +2.9% | $11.0M -44.0% | $19.7M | $1.1B | $1.0B | $1.2B |
| Other Income / Expenses | $13.6M +308.5% | $3.3M -72.4% | $12.0M +206.0% | -$11.3M +35.0% | -$17.5M | -$1.5B | $1.4B | $1.2B |
| Income Before Tax | -$49.3M +84.6% | -$320.5M +14.8% | -$376.1M -13.6% | -$331.2M -52.7% | -$216.9M | $3.3B | $4.9B | $3.6B |
| Pre-Tax Margin | -10.0% +127.4pp | -137.5% +121.5pp | -259.0% +43.6pp | -302.5% -138.0pp | -164.5% | 20.8% | 18.7% | 26.2% |
| Income Tax Expense | $988.0K +723.3% | $120.0K -46.2% | $223.0K -28.8% | $313.0K -23.5% | $409.0K | $1.3B | -$1.6B | $745.2M |
| Net Income | -$25.5M +92.1% | -$321.5M -188.6% | -$111.4M +60.0% | -$278.5M -54.6% | -$180.1M | $4.9B | $4.8B | $4.7B |
| Net Margin | -5.2% +132.7pp | -137.9% -61.2pp | -76.7% +177.7pp | -254.4% -117.8pp | -136.6% | 12.4% | 17.5% | 22.5% |
| EPS (Basic) | -$1 +86.3% | -$4 -172.0% | -$2 +65.7% | -$4 -45.2% | -$3 | $400.8M | $703.2M | $1.3B |
| EPS (Diluted) | -$1 +86.3% | -$4 -172.0% | -$2 +65.7% | -$4 -45.2% | -$3 | $766.2M | $609.4M | $452.6M |
| Weighted Avg Shares | $89.2M +13.1% | $78.9M +6.2% | $74.3M +16.5% | $63.8M +6.6% | $59.8M | $757.8M | $925.8M | $1.1B |
| Weighted Avg Shares (Diluted) | $89.2M +13.1% | $78.9M +6.2% | $74.3M +16.5% | $63.8M +6.6% | $59.8M | $1.2B | $924.4M | $678.0M |
Older periods hidden.
Sign in to unlockCompetitors
Peer companies in the same sector
Centessa Pharmaceuticals plc
NASDAQ:CNTA
$6.16B
Apogee Therapeutics, Inc.
NASDAQ:APGE
$5.47B
CG Oncology, Inc. Common stock
NASDAQ:CGON
$5.47B
Legend Biotech Corporation
NASDAQ:LEGN
$5.44B
Xenon Pharmaceuticals Inc.
NASDAQ:XENE
$4.21B
Celcuity Inc.
NASDAQ:CELC
$4.16B
Ultragenyx Pharmaceutical Inc.
NASDAQ:RARE
$2.73B
Disc Medicine, Inc.
NASDAQ:IRON
$2.72B
Tarsus Pharmaceuticals, Inc.
NASDAQ:TARS
$2.70B
Ascentage Pharma Group International
NASDAQ:AAPG
$398.35M
SEC Filings
Recent regulatory filings
No filings found.
How much revenue does TVTX generate?
Travere Therapeutics, Inc. (TVTX) reported $490.73M of revenue in fiscal 2025.
Is TVTX profitable?
Travere Therapeutics, Inc. (TVTX) reported -$25,546,000.00 of net income, with a net margin of -5.2%.
Explore More
Continue the stock analysis
Jump to another research area for this company.